Palisades Investment Partners’s SpringWorks Therapeutics SWTX Stock Holding History

Palisades Investment Partners’s Portfolio SWTX Stock Details SWTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-132,555	Closed	-$6.23M	–	51
2025 Q2	$6.23M	Sell	132,555 -3,923	-3%	-$175K	2.72%	14
2025 Q1	$6.02M	Buy	136,478 +2,033	+2%	+$93.6K	3.02%	14
2024 Q4	$4.86M	Buy	134,445 +12,154	+10%	+$425K	2.05%	20
2024 Q3	$3.92M	Buy	+122,291	New	+$4.57M	1.71%	20

Other funds holding SWTX

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Palisades Investment Partners's SWTX Position: Q3 2025 in Review

Palisades Investment Partners sold out of SpringWorks Therapeutics (SWTX) in Q3 2025, closing a stake of 132,555 shares — an estimated $6.23M sold.

Palisades Investment Partners first reported a position in SWTX in Q3 2024 and held it in 4 quarters. The position peaked at $6.23M in Q2 2025. 3 funds tracked by Wall St. Rank hold SWTX as of Q3 2025.

Palisades Investment Partners reported no remaining SpringWorks Therapeutics position as of Q3 2025 after selling out during the quarter.
Palisades Investment Partners sold 132,555 SpringWorks Therapeutics shares in Q3 2025, an estimated $6.23M.
Palisades Investment Partners first reported a position in SpringWorks Therapeutics in Q3 2024 and held it in 4 quarters.
Palisades Investment Partners's SpringWorks Therapeutics position peaked at $6.23M in Q2 2025.
3 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q3 2025.

Based on Palisades Investment Partners's 13F filing for Q3 2025, filed 30 Oct 2025.